@article{8137bb903fae421fa3a0ae8b4ba81b5b,
title = "Socio-demographic and trauma-related predictors of PTSD within 8 weeks of a motor vehicle collision in the AURORA study",
abstract = "This is the initial report of results from the AURORA multisite longitudinal study of adverse post-traumatic neuropsychiatric sequelae (APNS) among participants seeking emergency department (ED) treatment in the aftermath of a traumatic life experience. We focus on n = 666 participants presenting to EDs following a motor vehicle collision (MVC) and examine associations of participant socio-demographic and participant-reported MVC characteristics with 8-week posttraumatic stress disorder (PTSD) adjusting for pre-MVC PTSD and mediated by peritraumatic symptoms and 2-week acute stress disorder (ASD). Peritraumatic Symptoms, ASD, and PTSD were assessed with self-report scales. Eight-week PTSD prevalence was relatively high (42.0%) and positively associated with participant sex (female), low socioeconomic status (education and income), and several self-report indicators of MVC severity. Most of these associations were entirely mediated by peritraumatic symptoms and, to a lesser degree, ASD, suggesting that the first 2 weeks after trauma may be a uniquely important time period for intervening to prevent and reduce risk of PTSD. This observation, coupled with substantial variation in the relative strength of mediating pathways across predictors, raises the possibility of diverse and potentially complex underlying biological and psychological processes that remain to be elucidated with more in-depth analyses of the rich and evolving AURORA data.",
author = "Kessler, {Ronald C.} and Ressler, {Kerry J.} and House, {Stacey L.} and Beaudoin, {Francesca L.} and Xinming An and Stevens, {Jennifer S.} and Donglin Zeng and Neylan, {Thomas C.} and Linnstaedt, {Sarah D.} and Germine, {Laura T.} and Musey, {Paul I.} and Hendry, {Phyllis L.} and Sophia Sheikh and Storrow, {Alan B.} and Jones, {Christopher W.} and Punches, {Brittany E.} and Datner, {Elizabeth M.} and Kamran Mohiuddin and Gentile, {Nina T.} and McGrath, {Meghan E.} and {van Rooij}, {Sanne J.} and Hudak, {Lauren A.} and Haran, {John P.} and Peak, {David A.} and Domeier, {Robert M.} and Claire Pearson and Sanchez, {Leon D.} and Rathlev, {Niels K.} and Peacock, {William F.} and Bruce, {Steven E.} and Miller, {Mark W.} and Jutta Joormann and Barch, {Deanna M.} and Pizzagalli, {Diego A.} and Sheridan, {John F.} and Smoller, {Jordan W.} and Pace, {Thaddeus W.W.} and Harte, {Steven E.} and Elliott, {James M.} and Harnett, {Nathaniel G.} and Lebois, {Lauren A.M.} and Irving Hwang and Sampson, {Nancy A.} and Koenen, {Karestan C.} and McLean, {Samuel A.}",
note = "Funding Information: Conflict of interest JME reports support from the National Institutes of Health (NIH) through Grant Numbers R01HD079076 & R03HD094577: Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Center for Medical Rehabilitation Research. WFP is supported by research grants from Abbott, Boehringer Ingelheim, Braincheck, CSL Behring, Daiichi-Sankyo, Immunarray, Janssen, Ortho Clinical Diagnostics, Portola, Relypsa, Roche. He has served as a consultant for Abbott, Astra-Zeneca, Bayer, Beckman, Boehrhinger-Ingelheim, Ischemia Care, Dx, Immunarray, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, Salix, Siemens. He has also provided expert testimony for Johnson and Johnson. He owns stock or has ownership interest in AseptiScope Inc, Brainbox Inc, Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Ischemia DX LLC. Over the past three years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Posit Science, and Takeda Pharmaceuticals, as well as an honorarium from Alkermes for activities unrelated to the current project. LTG is on the scientific advisory board of the nonprofit Sage Bionetworks, for which she receives a small honorarium. She is also a consultant with 23andme, Inc. CWJ reports no direct conflicts related to this paper, and no ongoing conflicts. He has been an investigator on studies funded by Hologic Inc, Janssen, and AstraZeneca, for which his department has received research funding. NGH reports support from NIMH through grant number K00MH119603. LAML reports support from NIH/NIMH through grant K01MH118467. In the past 3 years, RCK received support for his epidemiological studies from Sanofi Aventis; was a consultant for Datastat, Inc., Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, and Takeda. KJR has served on advisory boards for Takeda, Resilience Therapeutics, Janssen and Verily/Google. His research has been sponsored by Alkermes and Brainsway and he has worked as a consultant for Alkermes. The remaining authors declare no conflicts of interest. Funding Information: Acknowledgements AURORA is supported by NIMH U01MH110925, the US Army Medical Research and Material Command, The One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mind-strong Health provide some of the hardware and software used to perform study assessments. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2021",
month = jul,
doi = "10.1038/s41380-020-00911-3",
language = "English",
volume = "26",
pages = "3108--3121",
journal = "Molecular Psychiatry",
issn = "1359-4184",
number = "7",
}